Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

U-M project to examine link between bipolar disorder and abnormalities in the circadian

A math professor at the University of Michigan will lead an international, $1 million project examining the links between bipolar disorder and abnormalities in the circadian, or daily, rhythms of a mammal's internal clock.

25 Apr 2012

AANF changes name to American Brain Foundation

The American Academy of Neurology Foundation is now the American Brain Foundation. The name change is part of an overall re-branding campaign as the organization repositions itself to become the world's leader in raising money for research to cure brain diseases, such as Alzheimer's disease, stroke, Parkinson's disease, autism, and epilepsy.

25 Apr 2012

LCP molecules can treat prion diseases

Toxic prions in the brain can be detected with self-illuminating polymers. The originators, at Linköping University in Sweden, has now shown that the same molecules can also render the prions harmless, and potentially cure fatal nerve-destroying illnesses.

25 Apr 2012

Mylan receives final FDA approval for generic Zyprexa ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Olanzapine Tablets USP, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg.

25 Apr 2012

Stress can shorten telomeres at a very young age

Children who have experienced violence might really be older than their years. The DNA of 10-year-olds who experienced violence in their young lives has been found to show wear and tear normally associated with aging, a Duke University study has found.

24 Apr 2012

Neuron-killing pathology of AD requires presence of a-beta and elevated p-tau levels

According to a new study, the neuron-killing pathology of Alzheimer's disease (AD), which begins before clinical symptoms appear, requires the presence of both amyloid-beta (a-beta) plaque deposits and elevated levels of an altered protein called p-tau.

24 Apr 2012

Immunosignatures can yield reliable and highly stable diagnostic results

Identifying diseases at an early, presymptomatic stage may offer the best chance for establishing proper treatment and improving patient outcomes. A new technique known as immunosignaturing harnesses the human immune system as an early warning sentry-one acutely sensitive to changes in the body that may be harbingers of illness.

24 Apr 2012

Preventive treatments can reduce migraine attacks

Research shows that many treatments can help prevent migraine in certain people, yet few people with migraine who are candidates for these preventive treatments actually use them, according to new guidelines issued by the American Academy of Neurology.

24 Apr 2012

Exercise staves off dementia in older women: Study

Older women with first signs of memory decline might ward off full-blown dementia by engaging in routine strength training according to a new study. However supervised weight-lifting seems to be working better than aerobics-based activity programs, the study found. The study was conducted with researchers from the Department of Psychology and Division of Geriatric Medicine at UBC, and Department of Psychology at the University of Iowa.

24 Apr 2012

RVX-208 molecule increases apolipoprotein A-I production

Resverlogix Corp. today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production.

23 Apr 2012

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately $2 million in Series A financing, which includes both issuance of new convertible preferred shares and debt conversion.

23 Apr 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

LCIG improves quality of life, reduces symptoms of Parkinson's

A recent clinical trial conducted at Evergreen Healthcare shows that a new form of a common drug used to treat Parkinson's Disease greatly improves the quality of life for patients and reduces the affects of symptoms such as tremors, slowness, stiffness and difficulty walking.

21 Apr 2012

Penn researchers continue efforts to differentiate Alzheimer's from FTLD

Teasing out the exact type or types of dementia someone suffers from is no easy task; neurodegenerative brain diseases share common pathology and often co-occur. Researchers from the Perelman School of Medicine at the University of Pennsylvania are continuing efforts to differentiate diseases, such as Alzheimer's disease (AD) from frontotemporal lobar degeneration (FTLD), as FTLD is often clinically difficult to distinguish from atypical presentations of AD.

21 Apr 2012

Scripps Florida scientist to develop new tests for aging and stress-associated diseases

A scientist from the Florida campus of The Scripps Research Institute has been awarded just over $1 million from the National Institutes of Health to develop a range of new tests that could lead to new treatments for a number of stress-associated and degenerative disorders of advancing age.

21 Apr 2012

First study to quantify effects of AD plaques on brain networks in animal model

Scientists studying the way Alzheimer's takes root in the brain have identified important new similarities between a mouse model and human Alzheimer's.

21 Apr 2012

Interferon beta-1a shows promise against MS

People who received injections of the multiple sclerosis (MS) drug interferon beta-1a soon after their first signs of possible MS were less likely to progress to clinically definite MS than people who switched to interferon beta-1a from placebo, according to new phase three results of the three-year REFLEXION clinical trial that will be presented as part of the Emerging Science program at the American Academy of Neurology's 64th Annual Meeting in New Orleans, April 21 to April 28, 2012.

20 Apr 2012

Therapeutic hypothermia reduces in-hospital deaths among sudden cardiac arrest patients

Forced body cooling known as therapeutic hypothermia has reduced in-hospital deaths among sudden cardiac arrest patients nearly 12 percent between 2001 and 2009, according to a Mayo Clinic study being presented at the upcoming American Academy of Neurology 2012 Annual Meeting in New Orleans.

20 Apr 2012

SK Biopharmaceuticals receives FDA Orphan Drug status for carisbamate

SK Biopharmaceuticals, a South Korean pharmaceutical company, announced today that it was granted special status by the U.S. Food and Drug Administration (FDA) for carisbamate for the management of patients with infantile spasms (IS), a form of epilepsy associated with increased risk of death or mental retardation.

20 Apr 2012

Even a little physical activity a day keeps Alzheimer’s away

It is estimated that by 2030, the number of people with Alzheimer's disease worldwide is expected to double to 80 million. A new study shows a ray of hope. It found that daily physical activity might provide a person's best chances of staving off the degenerative brain disorder - even if they're over 80 years old.Additionally exercise does not have to be strenuous. Activities such as cooking and cleaning also led to a protective benefit.

19 Apr 2012